Gt biopharma poster presentation and mini oral session at esmo congress 2022 demonstrates gtb-5550 trike® ability to specifically target and efficiently kill multiple b7h3+ solid and hematologic malignancies

Brisbane, calif., sept. 12, 2022 (globe newswire) --  gt biopharma, inc. (the “company” or “gtb”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced highlights of an accepted abstract titled, “b7h3-targeted tri-specific killer engagers deliver il-15 to nk cells but not t cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through nk cells,” for poster presentation both virtually at the european society for medical oncology ("esmo") congress 2022 being held at the paris expo porte de versailles from september 9-13, in paris, france.
GTBP Ratings Summary
GTBP Quant Ranking